AssayQuant Technologies
AssayQuant Technologies develops continuous real-time kinase and phosphatase activity assays using its patented PhosphoSens fluorescent sensor peptide platform, selling assay kits, recombinant enzymes, and KinSight profiling services to pharmaceutical, biotechnology, and academic drug discovery teams.
- Company typePrivate
- Founded2015
- HeadquartersMarlborough, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What AssayQuant Technologies does
AssayQuant Technologies is a privately held biotechnology company founded in 2015 and headquartered in Marlborough, Massachusetts, that develops and commercializes continuous enzyme activity assays for kinase and phosphatase drug discovery. Its core technology is the patented PhosphoSens platform, which uses proprietary Sox-based fluorescent sensor peptide substrates to convert phosphorylation events directly into continuous fluorescence readouts, generating real-time progress curves in every well rather than single endpoint measurements. The platform is delivered through three assay formats—PhosphoSens-Kinetic (continuous fluorescence intensity for kinetic insight), PhosphoSens-Red (time-resolved fluorescence for high-throughput screening), and PhosphoSens-Lysate (for unfractionated cell and tissue lysates)—and is supported by a catalog of 1,100+ active recombinant enzymes covering 510+ wild-type kinases, 420+ mutant kinases, 55+ lipid kinases, and 35+ phosphatases.
The company operates a dual business model combining catalog reagent sales and contract research services. Assay kits, substrates, and recombinant enzymes are sold directly through the company's e-commerce storefront and via global distributors under quote-based pricing with Net 30 terms. Complementing the catalog business, KinSight Services apply the same PhosphoSens technology in AssayQuant's laboratory to deliver kinase selectivity profiling (400+ wild-type kinases), phosphatase selectivity profiling, time-dependent inhibition characterization, compound testing, and custom assay development for pharmaceutical and biotechnology drug discovery teams. Customer segments include pharmaceutical companies, biotechnology companies, and academic research institutions engaged in kinase and phosphatase inhibitor discovery from target validation through preclinical testing.
The company is founder-led, with Erik Schaefer serving as Co-Founder, President, CEO, and CSO, and Barbara Imperiali as co-founder and CTO. It has raised approximately $9.6 million across two exempt securities offerings in May 2021 and July 2023, and operates with an 11-50 employee base from its Delaware-incorporated entity.
AssayQuant Technologies firmographics
Firmographics- Name
- AssayQuant Technologies
- Legal name
- AssayQuant Technologies, Inc.
- Website
- https://assayquant.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AssayQuant Technologies develops continuous real-time kinase and phosphatase activity assays using its patented PhosphoSens fluorescent sensor peptide platform, selling assay kits, recombinant enzymes, and KinSight profiling services to pharmaceutical, biotechnology, and academic drug discovery teams.
- Ownership category
- akta.pro rank
AssayQuant Technologies industry classification
Industry- Product category
- Drug Discovery Biochemical Assay Reagents
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
- akta.pro secondary industry
- Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL)
Keywords
Where AssayQuant Technologies is headquartered
LocationHeadquarters
- HQ city
- Marlborough
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
AssayQuant Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Revenue model
- Assay Kit and Reagent Sales: Sale of biochemical kinase and phosphatase activity assay kits, sensor substrates, and recombinant enzymes. Products include PhosphoSens-Kinetic, PhosphoSens-Red, and PhosphoSens-Lysate formats along with enzyme reagents.
- KinSight Services: Contract research services for compound profiling including kinase selectivity profiling (400+ WT kinases), phosphatase selectivity profiling, time-dependent inhibition characterization, compound testing, and custom assay development.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Catalog assay products available for direct purchase |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
AssayQuant Technologies product offering
Product offeringCore offering
AssayQuant Technologies develops and sells continuous kinetic biochemical assay products and contract research services for kinase and phosphatase drug discovery. Its core offering is the PhosphoSens Technology platform—fluorescent sensor peptide substrates that convert phosphorylation events into real-time fluorescent readouts—delivered through assay kits (PhosphoSens-Kinetic, PhosphoSens-Red, PhosphoSens-Lysate), a catalog of 1,100+ recombinant enzymes, and KinSight profiling services for compound selectivity and mechanism-of-inhibition characterization.
Product overview
AssayQuant Technologies offers a platform-plus-products architecture built on its proprietary PhosphoSens® Technology, which uses fluorescent sensor peptide substrates for continuous real-time measurement of kinase and phosphatase activity. The core platform is delivered through two assay formats: PhosphoSens-Kinetic (continuous fluorescence intensity for kinetic insight) and PhosphoSens-Red (time-resolved fluorescence for high-throughput screening), both supported by PhosphoSens-Lysate for cell/tissue lysate applications. These assay formats are available as individual product lines (Kinase Assays, Phosphatase Assays, Lysate Assays) and as part of a comprehensive recombinant enzyme portfolio spanning 900+ active kinases and 35+ phosphatases. Complementing the product catalog, KinSight Services apply the same PhosphoSens technology in AssayQuant's laboratory for compound profiling, selectivity assessment, and time-dependent inhibition characterization across hundreds of enzyme targets.
Differentiator
Problem solved
Functional benefit
Brands
- PhosphoSens: Core technology platform for continuous enzyme activity measurement using fluorescent sensor peptide substrates
- KinSight
Products and services
- PhosphoSens-Kinetic Assays Continuous fluorescence intensity assay kits that generate real-time kinetic progress curves of kinase and phosphatase activity in every well, enabling drug discovery researchers to characterize inhibitor potency, reversibility, and mechanism of action.
- PhosphoSens-Red Assays Time-resolved fluorescence assay kits optimized for high-throughput screening of compound libraries against kinase and phosphatase targets with reduced background interference.
- PhosphoSens-Lysate Assays Continuous fluorescence assay kits for measuring kinase activity and cell signaling directly in unfractionated cell or tissue lysates and tissue homogenates without prior fractionation.
- Kinase Assays Catalog line of validated kinase assay kits and reagents using PhosphoSens technology for real-time activity and inhibition measurement across multiple kinase targets and product configurations.
- Phosphatase Assays Catalog line of continuous, real-time phosphatase activity assay kits with multiple configurations and customizable reagent options for drug discovery applications.
- Lysate Assays Catalog line of assays using continuous fluorescence to measure kinase activity and cell signaling directly in unfractionated cell lysates and tissue homogenates.
- Recombinant Enzymes High-purity, assay-validated recombinant kinase and phosphatase enzyme catalog (510+ wild type protein kinases, 420+ mutant protein kinases, 55+ lipid kinases, 35+ protein phosphatases) designed for integration with PhosphoSens assays in basic research and preclinical drug discovery.
- KinSight Kinase Selectivity Profiling Contract research service that screens compounds against a panel of 400+ wild type protein kinases using continuous real-time PhosphoSens assays to characterize compound selectivity and mechanism of action.
- KinSight Phosphatase Selectivity Profiling Contract research service that measures compound potency and selectivity across phosphatase targets using continuous enzyme activity assays.
- Time-Dependent Inhibition Characterization Contract research service that quantifies inhibition kinetics and provides real-time data on inhibitor potency, reversibility, residence time, and inactivation kinetics using PhosphoSens assays.
- Compound Testing Services Laboratory service for testing client-supplied compounds using PhosphoSens technology assays to measure compound potency and mechanism of inhibition.
- Custom Assay Development Bespoke service that develops tailored kinase or phosphatase assays against client-specified targets in requested formats using the PhosphoSens technology.
Quantifiable outcome
- Real-time measurement captures inhibitor dynamics and reversibility mechanisms not visible in endpoint reads
Companies that use AssayQuant Technologies
Customer profileNamed customers3 records
Segments2 records
Ideal customer profiles2 records
AssayQuant Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
AssayQuant Technologies partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights5 records
AssayQuant Technologies competitors and assessment
Company assessmentDirect peers
- Eurofins DiscoverX: Offers KINOMEscan and related biochemical kinase/phosphatase profiling services and assays. Direct competitor to AssayQuant's KinSight selectivity profiling and kinase assay catalog.
- Reaction Biology Corporation: Provides kinase and phosphatase selectivity profiling services, including time-dependent inhibition characterization. Highly comparable to AssayQuant's KinSight offering in target classes and use cases.
- Carna Biosciences: Sells recombinant kinases, kinase assay kits, and kinase profiling services. Directly comparable to AssayQuant on recombinant enzyme portfolio and biochemical kinase assay product lines.
- BPS Bioscience: Supplies recombinant enzymes, biochemical assay kits, and custom assay development services for kinase and other drug-discovery targets. Closely comparable to AssayQuant's product and custom assay service mix.
- SignalChem Pharmaceuticals: Develops and sells recombinant kinases, assay kits, and profiling services. Overlaps directly with AssayQuant's enzyme catalog and kinase assay reagents.
Broad incumbents
- Promega Corporation: Large life-science tools vendor offering kinase assay kits (e.g., ADP-Glo) and biochemical reagents. Competes in the same customer workflows but as part of a much broader portfolio.
- Revvity: Successor to PerkinElmer's life sciences business, offering HTRF and LANCE kinase assay technologies. Competes directly with PhosphoSens formats in pharma screening labs.
- Thermo Fisher Scientific: Sells SelectScreen kinase profiling services, LanthaScreen and Z'-LYTE kinase assay kits, and recombinant kinases. Competes across AssayQuant's product and service lines as part of a much larger portfolio.
- Eurofins Scientific: Global CRO including Eurofins DiscoverX with broad kinase/phosphatase profiling capabilities. Competes with KinSight services but operates at significantly larger scale.
- MilliporeSigma (Merck KGaA Life Science): Supplies kinase assay kits, recombinant enzymes, and profiling services through its life-science portfolio. Competes with AssayQuant in both catalog reagents and CRO services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
AssayQuant Technologies social profiles
Digital presenceAssayQuant Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
AssayQuant Technologies leadership team
Management profileNumber of profiles
Profiles3 records
AssayQuant Technologies funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AssayQuant Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AssayQuant Technologies
What does AssayQuant Technologies do?
AssayQuant Technologies develops and sells continuous kinetic biochemical assay products and contract research services for kinase and phosphatase drug discovery. Its core offering is the PhosphoSens Technology platform—fluorescent sensor peptide substrates that convert phosphorylation events into real-time fluorescent readouts—delivered through assay kits (PhosphoSens-Kinetic, PhosphoSens-Red, PhosphoSens-Lysate), a catalog of 1,100+ recombinant enzymes, and KinSight profiling services for compound selectivity and mechanism-of-inhibition characterization.
Is AssayQuant Technologies a public or private company?
AssayQuant Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AssayQuant Technologies founded?
AssayQuant Technologies was founded in 2015. It employs 11 to 50 people.
Where is AssayQuant Technologies based?
AssayQuant Technologies is headquartered in Marlborough, United States, in the North America region.
How does AssayQuant Technologies make money?
Two revenue lines are on record. Assay Kit and Reagent Sales are the primary driver. The others are kinSight Services.
Who are AssayQuant Technologies's main competitors?
Direct peers on record are Eurofins DiscoverX, Reaction Biology Corporation, Carna Biosciences, BPS Bioscience and SignalChem Pharmaceuticals. Broad incumbents are Promega Corporation, Revvity, Thermo Fisher Scientific, Eurofins Scientific and MilliporeSigma (Merck KGaA Life Science).
Does AssayQuant Technologies have an API?
No public API is recorded for AssayQuant Technologies.
What industry is AssayQuant Technologies in?
AssayQuant Technologies's product category is Drug Discovery Biochemical Assay Reagents. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 541714 and its SIC code is 8731.